Jump to content

Stimuvax Cancer Vaccine Safe to Use in Long-Term Phase II


Recommended Posts

http://www.reuters.com/article/rbssBiot ... 8220090530


. . . . . . . . .

Merck KGaA's says cancer vaccine safe in study

Sat May 30, 2009 8:00am EDT

FRANKFURT, May 30 (Reuters) - Merck KGaA's (MRCG.DE: Quote, Profile, Research, Stock Buzz) experimental cancer vaccine Stimuvax proved safe to use in a long-term Phase II study on lung cancer patients, the German drugmaker said on Saturday.

The trial showed that patients' immune systems did not turn on normal cells, a major concern in new vaccines that are designed to prime the body's immune system to detect and attack cancer cells.

The study involved lung-cancer patients whose tumours had started to spread and long-term data was derived from 16 participants treated for between two and eight years.

The most common side effects were mild injection site reactions and nausea, according to a statement from Merck.

Results from the Phase II study encouraged Merck in February 2007 to take Stimuvax, which it co-develops with U.S. biotech firm Oncothyreon (ONTY.O: Quote, Profile, Research, Stock Buzz), to the third and last phase of testing usually required for regulatory approval.

Germany's Merck is racing with biotech firms including Transgene (TRNG.PA: Quote, Profile, Research, Stock Buzz), Dendreon Corp (DNDN.O: Quote, Profile, Research, Stock Buzz) and Antigenics (AGEN.O: Quote, Profile, Research, Stock Buzz) to bring cancer vaccines to market.

While Transgene's TG4010 compound also targets lung tumours, the most common form of cancer, the Dendreon and Antigenics drug candidates are aimed at prostate cancer and brain cancer, respectively. (Reporting by Ludwig Burger; Editing by Dhara Ranasinghe)

© Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.

Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

. . . . . . . . .

(Reuters, May 30, 2009)


The information contained in these articles may or may not be in agreement with my own opinions. They are not being posted with the intention of being medical advice of any kind.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.